Evidence map›Paper›PMID 31757220›Full record

ArticleJournal of neuroinflammation2019

Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions.

Miguel Angel Abellanas, Marta Zamarbide, Leyre Basurco, Esther Luquin, Marta Garcia-Granero, Pedro Clavero, Patxi San Martin-Uriz, Amaia Vilas, Elisa Mengual, Sandra Hervas-Stubbs and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. iScience · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Immunogenetics of Multiple Sclerosis in Romanian Patients: Preliminary Data.International journal of molecular sciences · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Neuroprotective Effects of Dexamethasone in a Neuromelanin-Driven Parkinson's Disease Model.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Miguel Angel AbellanasDepartamento de Bioquímica y Genética, Universidad de Navarra, Facultad de Ciencias, Pamplona, Spain.
Marta ZamarbideUniversidad de Navarra, CIMA, Programa de Neurociencias, Pamplona, Spain.
Leyre BasurcoDepartamento de Bioquímica y Genética, Universidad de Navarra, Facultad de Ciencias, Pamplona, Spain.
Esther LuquinDepartamento de Patología, Anatomía y Fisiología, Universidad de Navarra, Facultad de Medicina, Pamplona, Spain.
Marta Garcia-GraneroDepartamento de Bioquímica y Genética, Universidad de Navarra, Facultad de Ciencias, Pamplona, Spain.
Pedro ClaveroServicio de Neurología, Complejo Hospitalario de Navarra, Pamplona, Spain.
Patxi San Martin-UrizUniversidad de Navarra, CIMA, Programa de Oncohematología, Pamplona, Spain.
Amaia VilasUniversidad de Navarra, CIMA, Programa de Oncohematología, Pamplona, Spain.
Elisa MengualDepartamento de Patología, Anatomía y Fisiología, Universidad de Navarra, Facultad de Medicina, Pamplona, Spain.
Sandra Hervas-StubbsUniversidad de Navarra, CIMA, Programa de Inmunología, Pamplona, Spain.
Maria S AymerichDepartamento de Bioquímica y Genética, Universidad de Navarra, Facultad de Ciencias, Pamplona, Spain. maymerich@unav.es.ORCID http://orcid.org/0000-0001-9750-1538
Universidad de Navarra · ESComplejo Hospitalario de Navarra · ESNavarre Institute of Health Research · ES

Funding

Instituto de Salud Carlos III PI17/01931
6 · The paper itself

Abstract

backgroundInflammation is a critical process for the progression of neuronal death in neurodegenerative disorders. Microglia play a central role in neuroinflammation and may affect neuron vulnerability. Next generation sequencing has shown the molecular heterogeneity of microglial cells; however, the variability in their response to pathological inputs remains unknown.

methodsTo determine the effect of an inflammatory stimulus on microglial cells, lipopolysaccharide (LPS) was administered peripherally to mice and the inflammatory status of the cortex, hippocampus, midbrain, and striatum was assessed. Microglial activation and interaction with the immune system were analyzed in single cell suspensions obtained from the different brain regions by fluorescence-activated cell sorting, next generation RNA sequencing, real-time PCR, and immunohistochemical techniques. Antigen-presenting properties of microglia were evaluated by the ability of isolated cells to induce a clonal expansion of CD4

resultsUnder steady-state conditions, the midbrain presented a high immune-alert state characterized by the presence of two unique microglial subpopulations, one expressing the major histocompatibility complex class II (MHC-II) and acting as antigen-presenting cells and another expressing the toll-like receptor 4 (TLR4), and by the presence of a higher proportion of infiltrating CD4

conclusionsThese data show that the midbrain presents a high immune-alert state under steady-state conditions that elicits a specific immune-suppressive response when exposed to an inflammatory stimulus. This specific inflammatory tone and response may have an impact in neuronal viability.

Indexed as

AnimalsAntigens, CDFlow CytometryImmunity, InnateInflammationLipopolysaccharidesMaleMesencephalonMiceMicrogliaAntigens, CDLipopolysaccharidesAntigen-presenting cellsInnate immunityLPSMHC-IIMicrogliaMidbrainTGFβTreg

Identifiers

PMID31757220
PMCPMC6874825
OpenAlexW2989702665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.